Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May-Jun;33(3):253-6.
doi: 10.4103/0970-2113.180800.

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai

Zarir F Udwadia  1 , Jai Bharat Mullerpattan  1 , Kushal D Shah  1 , Camilla S Rodrigues  2
Affiliations

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai

Zarir F Udwadia et al. Lung India. 2016 May-Jun.

Abstract

Background: Treatment of multidrug-resistant tuberculosis (MDR-TB) in the Programmatic Management of Drug-resistant TB program involves a standard regimen with a 6-month intensive phase and an 18-month continuation phase. However, the local drug resistance patterns in high MDR regions such as Mumbai may not be adequately reflected in the design of the regimen for that particular area.

Setting: The study was carried out at a private Tertiary Level Hospital in Mumbai in a mycobacteriology laboratory equipped to perform the second-line drug susceptibility testing (DST).

Objective: We attempted to analyze the impact of prescribing the standardized Category IV regimen to all patients receiving a DST at our mycobacteriology laboratory.

Materials and methods: All samples confirmed to be MDR-TB and tested for the second-line drugs at Hinduja Hospital's Mycobacteriology Laboratory in the year 2012 were analyzed.

Results: A total of 1539 samples were analyzed. Of these, 464 (30.14%) were MDR-TB, 867 (56.33%) were MDR with fluoroquinolone resistance, and 198 (12.8%) were extensively drug-resistant TB. The average number of susceptible drugs per sample was 3.07 ± 1.29 (assuming 100% cycloserine susceptibility). Taking 4 effective drugs to be the cut or an effective regimen, the number of patients receiving 4 or more effective drugs from the standardized directly observed treatment, short-course plus regimen would be 516 (33.5%) while 66.5% of cases would receive 3 or less effective drugs.

Conclusion: Our study shows that a high proportion of patients will have resistance to a number of the first- and second-line drugs. Local epidemiology must be factored in to avoid amplification of resistance.

Keywords: Category IV treatment; directly observed treatment short-course plus; drug-resistant tuberculosis.

PubMed Disclaimer

References

    1. Revised National Tuberculosis Programme (RNTCP) – TBC India. [Last accessed on 2015 Feb 08]. Available from: http://www.tbcindia.nic.in/rntcp.html .
    1. World Health Organization. Global Tuberculosis Report 2013. Geneva, Switzerland: World Health Organization; 2013.
    1. New Delhi: Central TB Division; 2012. Revised National Tuberculosis Control Programme. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis (PMDT) in India.
    1. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis. 2009;13:79–83. - PubMed
    1. Geneva, Switzerland: World Health Organization; 2011. World Health Organization. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis: 2011 Update. - PubMed